H. Lundbeck (CPSE:HLUN B) Could Be 6% Undervalued Following Fresh Clinical Data

H. Lundbeck (CPSE:HLUN B) is back in focus after releasing fresh clinical data for two key pipeline assets: Parkinson’s candidate Lu AF28996 and migraine drug eptinezumab, around its presentations at the MDS 2026 congress.

Investors have been responding to this stream of trial updates, with H. Lundbeck’s share price at DKK46.3 after a 4.9% 7-day share price return and an 11.8% 90-day share price return. The 3-year total shareholder return of 27.3% points to gradually building momentum.

Scan 126 healthcare AI stocks to see which other treatment-focused companies, alongside H. Lundbeck, are drawing attention with fresh clinical data and specialist neurological or migraine pipelines.

The question for H. Lundbeck now is simple. After the recent clinical headlines and a DKK46.3 share price, does it make more sense to step in here or wait for a cleaner valuation setup in the next section?

Most Popular Narrative: 6% Undervalued

H. Lundbeck’s most followed narrative points to a fair value of DKK49.19 per share, compared with the latest close at DKK46.3. That gap keeps the focus squarely on how concentrated brands and the neuroscience pipeline could justify any valuation upside.

The main factor that has to go right is successful execution of the Focused Innovator model, in which sustained high R&D investment translates into commercially relevant approvals across migraine prevention and rare or severe neuroscience indications.

The current valuation and this narrative’s bearish stance together suggest that the share price broadly reflects H. Lundbeck’s existing growth drivers and pipeline progress, leaving limited margin for error if execution or key products underperform.

See why 15 investors see H. Lundbeck as 6% undervalued.

Result: Fair Value of DKK49.19 (UNDERVALUED)

Still, heavy dependence on a few branded treatments and the shift to partner markets could undermine the H. Lundbeck narrative if prescriptions or margins disappoint.

Find out about the key risks to this H. Lundbeck narrative.

Next Steps

Sentiment on H. Lundbeck is mixed, with both risk flags and genuine bright spots in the story. Move quickly, stress test the numbers and weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond H. Lundbeck?

Do not stop at one opportunity. Use the Simply Wall Street Screener to widen your watchlist and pressure test every idea against clear, data driven filters.

• Target deep value opportunities by scanning for companies that combine quality fundamentals with compressed valuations using the 180 high quality undervalued stocks.
• Lock in potential income streams by focusing on businesses that offer higher yields with resilient payout profiles through the 217 dividend fortresses.
• Dial down portfolio stress by concentrating on resilient businesses with stronger financial risk profiles using the 225 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com